Structure-Activity Relationship Study of CYM51010, an agonist for the µ-δ Opioid Receptor Heterodimer.


Journal

Chemical & pharmaceutical bulletin
ISSN: 1347-5223
Titre abrégé: Chem Pharm Bull (Tokyo)
Pays: Japan
ID NLM: 0377775

Informations de publication

Date de publication:
2024
Historique:
medline: 1 8 2024
pubmed: 1 8 2024
entrez: 31 7 2024
Statut: ppublish

Résumé

Although opioid analgesics are indispensable in treating pain, these drugs are accompanied by life-threatening side effects. While clinically relevant opioid drugs target the µ opioid receptor (MOR), a heterodimer between the MOR and the δ opioid receptor (DOR) has emerged as another target to develop safer analgesics. Although some heterodimer-preferring agonists have been reported so far, it is still difficult to activate the MOR/DOR heterodimer selectively in the presence of MOR or DOR monomers/homodimers. To gain insights to develop selective agonists for MOR/DOR, herein we prepared analogs of CYM51010, one of the reported heterodimer-preferring agonists, and collected structure-activity relationship information. We found that the ethoxycarbonyl group was needed for the activity for the heterodimer, although this group could be substituted with functional groups with similar sizes, such as an ethoxycarbonyl group. As for the acetylaminophenyl group, not a type of substituent, but rather a substituent located at a specific position (para-position) was essential for the activity. Changing the linker length between the acetylaminophenyl group and the piperidine moiety also had deleterious effects on the activity. On the other hand, the substitution of the acetylamino group with a trifluoroacetylamino group and the substitution of the phenethyl group with a benzyl group diminished the activities for the monomers/homodimers while keeping the activity for MOR/DOR, which enhanced the selectivity. Our findings herein will play an important role in developing selective agonists for MOR/DOR and for elucidating the physiological roles of this heterodimer in analgesic processes and in the establishment of side effects.

Identifiants

pubmed: 39085079
doi: 10.1248/cpb.c24-00188
doi:

Substances chimiques

Receptors, Opioid, delta 0
Receptors, Opioid, mu 0
Analgesics, Opioid 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

711-730

Auteurs

Ayaka Watanabe (A)

Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University.

Shuma Yamada (S)

Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University.

Haruka Yoshida (H)

Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University.
Department of Pain Control Research, The Jikei University School of Medicine.

Miku Inagaki (M)

Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University.
Department of Pain Control Research, The Jikei University School of Medicine.

Nao Atsumi (N)

Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University.
Department of Pain Control Research, The Jikei University School of Medicine.

Aoba Matsushima (A)

Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University.

Naoki Takahashi (N)

Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University.

Naoto Ishibashi (N)

Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University.
Department of Pain Control Research, The Jikei University School of Medicine.

Takumi Ogino (T)

Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University.
Department of Pain Control Research, The Jikei University School of Medicine.

Ryoto Someya (R)

Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University.
Department of Pain Control Research, The Jikei University School of Medicine.

Ai Taguchi (A)

Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University.
Department of Pain Control Research, The Jikei University School of Medicine.

Ryo Kagaya (R)

Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University.
Department of Pain Control Research, The Jikei University School of Medicine.

Karin Ashizawa (K)

Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University.
Department of Pain Control Research, The Jikei University School of Medicine.

Hinako Mendori (H)

Department of Pain Control Research, The Jikei University School of Medicine.
Laboratory of Molecular Pathology and Metabolic Disease, Faculty of Pharmaceutical Sciences, Tokyo University of Science.

Yusuke Karasawa (Y)

Department of Pain Control Research, The Jikei University School of Medicine.

Kaori Ohshima (K)

Department of Pain Control Research, The Jikei University School of Medicine.

Akinobu Yokoyama (A)

Laboratory of Molecular Pathology and Metabolic Disease, Faculty of Pharmaceutical Sciences, Tokyo University of Science.

Miki Nonaka (M)

Department of Pain Control Research, The Jikei University School of Medicine.

Kanako Miyano (K)

Department of Pain Control Research, The Jikei University School of Medicine.

Fumika Karaki (F)

Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University.
Medicinal Research Laboratories, School of Pharmacy, Kitasato University.

Shigeto Hirayama (S)

Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University.
Medicinal Research Laboratories, School of Pharmacy, Kitasato University.

Kennosuke Itoh (K)

Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University.
Medicinal Research Laboratories, School of Pharmacy, Kitasato University.

Yasuhito Uezono (Y)

Department of Pain Control Research, The Jikei University School of Medicine.

Hideaki Fujii (H)

Laboratory of Medicinal Chemistry, School of Pharmacy, Kitasato University.
Medicinal Research Laboratories, School of Pharmacy, Kitasato University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH